Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-08
2008-04-08
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S050000
Reexamination Certificate
active
07354915
ABSTRACT:
Compounds having the structure of formula I are provided. In formula I, R1is H, OH, substituted or unsubstituted C1to C3alkyl, C1to C3perfluoroalkyl, or COR6; R6is H, substituted or unsubstituted C1to C4alkyl, aryl, substituted or unsubstituted C1to C4alkoxy, substituted or unsubstituted C1to C3aminoalkyl; R2and R3are H, substituted or unsubstituted C1to C6alkyl, C1to C6perfluoroalkyl, substituted or unsubstituted C2to C6alkenyl, substituted or unsubstituted C2to C6alkynyl, substituted or unsubstituted C3to C6cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclic; or R2and R3are fused to form spirocyclic rings; R4is NHR7, OR7, NHSO2R7, or OSO2R7; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt, ester, or prodrug thereof. Such compounds are useful as progesterone receptor modulators and for treating progesterone receptor related conditions
REFERENCES:
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 5874430 (1999-02-01), Christ et al.
patent: 6306851 (2001-10-01), Santilli et al.
patent: 6339098 (2002-01-01), Collins et al.
patent: 6355648 (2002-03-01), Fensome et al.
patent: 6358948 (2002-03-01), Zhang et al.
patent: 6369056 (2002-04-01), Zhang et al.
patent: 6380235 (2002-04-01), Zhang et al.
patent: 6391907 (2002-05-01), Fensome et al.
patent: 6407101 (2002-06-01), Collins et al.
patent: 6417214 (2002-07-01), Ullrich et al.
patent: 6436929 (2002-08-01), Zhang et al.
patent: 6441019 (2002-08-01), Santilli et al.
patent: 6509334 (2003-01-01), Zhang et al.
patent: 6521657 (2003-02-01), Fensome et al.
patent: 6566358 (2003-05-01), Zhang et al.
patent: 6583145 (2003-06-01), Fensome et al.
patent: 6608068 (2003-08-01), Fensome et al.
patent: 6693103 (2004-02-01), Zhang et al.
patent: 6713478 (2004-03-01), Zhang et al.
patent: 6841568 (2005-01-01), Fensome et al.
patent: 6946454 (2005-09-01), Fensome et al.
patent: 7081457 (2006-07-01), Zhang et al.
patent: 7084168 (2006-08-01), Fensome et al.
patent: 7091234 (2006-08-01), Fensome et al.
patent: 2002/0115853 (2002-08-01), Zhang et al.
patent: 2004/0186101 (2004-09-01), Zhang et al.
patent: 2005/0085470 (2005-04-01), Zhang et al.
patent: 2006/0160882 (2006-07-01), Fensome et al.
patent: WO 00/66555 (2000-11-01), None
patent: WO 00/66556 (2000-11-01), None
patent: WO 00/66560 (2000-11-01), None
patent: WO 00/66564 (2000-11-01), None
patent: WO 00/66570 (2000-11-01), None
patent: WO 00/66571 (2000-11-01), None
patent: WO 00/66591 (2000-11-01), None
patent: WO 00/66592 (2000-11-01), None
patent: WO 01/16108 (2001-03-01), None
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Combs et al., “Nonsteroidal Progesterone Receptor Ligands. 2. High-Affinity Ligands with Selectivity for Bone cell Progesterone Receptors”, Journal of Medicinal Chemistry, 38(25):4880-4884, (1995).
Hamann et al., “Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists”, Annals New York Academy of Sciences, 761:383-387, (Jun. 12, 1995).
Horwitz et al., “Progestins, Progesterone Receptors, and Breast Cancer”, Hormones and Cancer, 283-306, (1996).
Kekkonen et al., “Sequential Regimen of the Antiprogesterone RU486 and Synthetic Progestin for Contraception”, Fertility and Sterility, 60(4):610-615, (Oct. 1993).
Kettel et al., “Endocrine Responses to Long-Term Administration of the Antiprogesterone RU486 in Patients with Pelvic Endometriosis”, Fertility and Sterility, 56(3):402-407, (Sep. 1991).
Kurihara et al., “Synthesis of (±)-PF1092A, B, C; New Nonsteroidal Progesterone Receptor Ligands”, The Journal of Antibiotics, 50(4):360-362, (Apr. 1997).
Mangelsdorf et al., “The Nuclear Receptor Superfamily: The Second Decade”, Cell, 83:835-839, (Dec. 15, 1995).
Michna et al., “Differentiation Therapy with Progesterone Antagonists”, Ann. N.Y. Acad. Sci., 761:224-247, (Jun. 12, 1995).
Murphy et al., “Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU 486”, Journal of Clinical Endocrinology and Metabolism, 76(2):513-517, (Feb. 1993).
Perlman et al., “20-Oxopregnacalciferols: Vitamin D Compounds that bind the Progesterone Receptor”, Tetrahedron Letters, 35(15):2295-2298, (1994).
Tegley et al., “5-Benzylidene 1,2-Dihydrochromeno[3,4-f]Quinolines, A Novel Class of nonsteroidal Human Progesterone Receptor Agonists”, J. Med. Chem., 41(22):4354-4359, (Oct. 22, 1998).
Ulmann et al., “Clinical Uses of Mifepristone (MFP)”, Ann. N.Y. Acad. Sci., 761:248-260, (Jun. 12, 1995).
Zhi et al., “Nonsteroidal Progesterone Receptor Antagonists based on 6-Thiophenehydroquinolines”, Bioorg. Med. Chem. Lett. 10(5):415-418, (Mar. 6, 2000).
Zhi et al., “5-Aryl-1,2-dihydrochromeno[3,4-f]Quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists”, J. Med. Chem.., 41(3):291-302, (Jan. 29, 1998).
Banker et al., Modern Pharmaceutics, 3rdEdition, Marcel Dekker, NY, pp. 451 and 596, (1996).
Wolff, Burger's Medicinal Chemistry and Drug Discovery, 5thEdition, Part 1, John Wiley & Sons, pp. 975-977, (1995).
Wiebe, “Progesterone Metabolites in Breast Cancer”, Endocrine-Related Cancer, 13(3):717-738, (Sep. 2006).
Kern Jeffrey
Zhang Puwen
Habte Kahsay T
Howson & Howson LLP
Milowsy Arnold S.
Wyeth
LandOfFree
6-amino-1,4-dihydro-benzo[ d ][1,3]oxazin-2-ones and analogs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-amino-1,4-dihydro-benzo[ d ][1,3]oxazin-2-ones and analogs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-amino-1,4-dihydro-benzo[ d ][1,3]oxazin-2-ones and analogs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2778372